Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Krauth, MT; Burgstaller, S; Buxhofer-Ausch, V; Gastl, G; Geissler, K; Keil, F; Krippl, P; Melchardt, T; Petzer, A; Rumpold, H; Sliwa, T; Wöhrer, S; Wölfler, A; Gisslinger, H.
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.
WIEN KLIN WOCHENSCHR. 2018; 130(17-18): 495-504.
Doi: 10.1007/s00508-018-1365-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Krippl Peter
- Wölfler Albert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. Since its introduction, the expertise of prescribing doctors with respect to ruxolitinib function, efficacy and adverse effects has consistently been augmented, resulting in therapy modalities that are better tailored to individual patients as well as in increased safety of the treatment. The present consensus on ruxolitinib therapy management has been elaborated by Austrian experts in myeloproliferative neoplasms in line with international treatment guidelines. Our recommendations aim to contribute to an improved management of patients with myelofibrosis treated with ruxolitinib.
- Find related publications in this database (using NLM MeSH Indexing)
- -
- Consensus -
- Consensus -
- Humans -
- Primary Myelofibrosis - drug therapy
- Pyrazoles - therapeutic use
- Retrospective Studies -
- Find related publications in this database (Keywords)
- Janus kinase 2
- Myeloproliferative disorders
- Primary myelofibrosis
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis